A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract
The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect in vivo drug release from oral dosage forms. There is still relatively little information on the mechanical destructive force in the GI trac...
Saved in:
Published in | International journal of pharmaceutics Vol. 208; no. 1; pp. 61 - 70 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier B.V
04.11.2000
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 0378-5173 1873-3476 |
DOI | 10.1016/S0378-5173(00)00552-4 |
Cover
Loading…
Abstract | The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect in vivo drug release from oral dosage forms. There is still relatively little information on the mechanical destructive force in the GI tract. Press-coated tablets with an extremely brittle outer layer were developed using a unique, highly hydrophobic Teflon powder that could be shaped with weak compression force. A marker drug contained in the tablets was released only when the tablets received a force larger than its predetermined crushing strength. We referred to this type of tablet as a ‘destructive force dependent release system’ (DDRS). A total of nine healthy, male subjects were orally administered the tablets under fed and/or fasting conditions. Tablets with a predetermined crushing strength of 1.50 N were crushed by all of the four subjects who took them under fed conditions and two of the five subjects under fasting conditions. Tablets with a crushing strength of 1.89 N were crushed by two of the six subjects who took them under fed conditions and none of the five subjects under fasting conditions. The range of mechanical destructive force in the human stomach was obtained. |
---|---|
AbstractList | The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect in vivo drug release from oral dosage forms. There is still relatively little information on the mechanical destructive force in the GI tract. Press-coated tablets with an extremely brittle outer layer were developed using a unique, highly hydrophobic Teflon powder that could be shaped with weak compression force. A marker drug contained in the tablets was released only when the tablets received a force larger than its predetermined crushing strength. We referred to this type of tablet as a 'destructive force dependent release system' (DDRS). A total of nine healthy, male subjects were orally administered the tablets under fed and/or fasting conditions. Tablets with a predetermined crushing strength of 1.50 N were crushed by all of the four subjects who took them under fed conditions and two of the five subjects under fasting conditions. Tablets with a crushing strength of 1.89 N were crushed by two of the six subjects who took them under fed conditions and none of the five subjects under fasting conditions. The range of mechanical destructive force in the human stomach was obtained.The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect in vivo drug release from oral dosage forms. There is still relatively little information on the mechanical destructive force in the GI tract. Press-coated tablets with an extremely brittle outer layer were developed using a unique, highly hydrophobic Teflon powder that could be shaped with weak compression force. A marker drug contained in the tablets was released only when the tablets received a force larger than its predetermined crushing strength. We referred to this type of tablet as a 'destructive force dependent release system' (DDRS). A total of nine healthy, male subjects were orally administered the tablets under fed and/or fasting conditions. Tablets with a predetermined crushing strength of 1.50 N were crushed by all of the four subjects who took them under fed conditions and two of the five subjects under fasting conditions. Tablets with a crushing strength of 1.89 N were crushed by two of the six subjects who took them under fed conditions and none of the five subjects under fasting conditions. The range of mechanical destructive force in the human stomach was obtained. The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect in vivo drug release from oral dosage forms. There is still relatively little information on the mechanical destructive force in the GI tract. Press-coated tablets with an extremely brittle outer layer were developed using a unique, highly hydrophobic Teflon powder that could be shaped with weak compression force. A marker drug contained in the tablets was released only when the tablets received a force larger than its predetermined crushing strength. We referred to this type of tablet as a 'destructive force dependent release system' (DDRS). A total of nine healthy, male subjects were orally administered the tablets under fed and/or fasting conditions. Tablets with a predetermined crushing strength of 1.50 N were crushed by all of the four subjects who took them under fed conditions and two of the five subjects under fasting conditions. Tablets with a crushing strength of 1.89 N were crushed by two of the six subjects who took them under fed conditions and none of the five subjects under fasting conditions. The range of mechanical destructive force in the human stomach was obtained. |
Author | Kusai, Akira Ikeda, Masaru Nishimura, Kenji Kamba, Masaharu Seta, Yasuo |
Author_xml | – sequence: 1 givenname: Masaharu surname: Kamba fullname: Kamba, Masaharu email: kmash@shina.sankyo.co.jp organization: Product Development Laboratories, Sankyo Co., Ltd, 2-58, 1-chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan – sequence: 2 givenname: Yasuo surname: Seta fullname: Seta, Yasuo organization: Product Development Laboratories, Sankyo Co., Ltd, 2-58, 1-chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan – sequence: 3 givenname: Akira surname: Kusai fullname: Kusai, Akira organization: Product Development Laboratories, Sankyo Co., Ltd, 2-58, 1-chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan – sequence: 4 givenname: Masaru surname: Ikeda fullname: Ikeda, Masaru organization: Product Development Laboratories, Sankyo Co., Ltd, 2-58, 1-chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan – sequence: 5 givenname: Kenji surname: Nishimura fullname: Nishimura, Kenji organization: Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co. Ltd, 2-58, 1-chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1523101$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11064212$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUtvFDEQhC0URDaBnwCaA0LhMNC2x_NQDiiKwkOKxAE4W552T2I0YwfbsxL_Hmd3CRKXnPrQX1Wruk7YkQ-eGHvJ4R0H3r7_BrLra8U7eQbwFkApUTdP2Ib3naxl07VHbPOAHLOTlH4CQCu4fMaOOYe2EVxsmL6oVu9-rVTZkMwNVVOIS5VDRVszryZTlW-pWghvjXdo5spSynHF7LY7FqlyfsfcmLIIzucCOF_IHA3m5-zpZOZELw7zlP34ePX98nN9_fXTl8uL6xrlALkeANuu61urJmzlJJXCYRxQdJNVEix2g-G2pd4KI5sBoSQT40QNDDSOUpA8ZW_2vncxlDQp68UlpHk2nsKadCfKHaH6Ar46gOu4kNV30S0m_tZ_X1KA1wfApBJ4isajS_84JWQpoGDnewxjSCnSpNFlk13wJbebNQd935Pe9aTvS9AAeteTbopa_ad-8H9E92Gvo_LLraOoEzrySNZFwqxtcI84_AF2P6ok |
CODEN | IJPHDE |
CitedBy_id | crossref_primary_10_1111_ijfs_16927 crossref_primary_10_3897_pharmacia_70_e111731 crossref_primary_10_1111_j_1750_3841_2008_00766_x crossref_primary_10_1146_annurev_food_030713_092315 crossref_primary_10_1016_j_ijpharm_2013_08_077 crossref_primary_10_1021_acsbiomaterials_8b01040 crossref_primary_10_1016_j_foodres_2023_112810 crossref_primary_10_1248_bpb_26_1442 crossref_primary_10_3109_1061186X_2010_504264 crossref_primary_10_1248_cpb_56_792 crossref_primary_10_1016_j_ejpb_2019_01_026 crossref_primary_10_1016_S0939_6411_03_00136_X crossref_primary_10_1007_s13346_021_00905_w crossref_primary_10_1016_j_ejps_2009_06_010 crossref_primary_10_1016_j_ijpharm_2016_10_069 crossref_primary_10_1111_j_1750_3841_2010_01856_x crossref_primary_10_1248_cpb_55_1574 crossref_primary_10_3136_nskkk_65_543 crossref_primary_10_1016_j_ejpb_2013_12_008 crossref_primary_10_1016_j_jfoodeng_2019_07_021 crossref_primary_10_1208_s12249_013_0050_2 crossref_primary_10_1039_C4FO00041B crossref_primary_10_1016_j_ejpb_2007_03_002 crossref_primary_10_1208_s12249_014_0246_0 crossref_primary_10_1016_j_foodres_2019_04_015 crossref_primary_10_1208_s12249_018_1022_3 crossref_primary_10_1016_j_asej_2021_02_033 crossref_primary_10_1016_j_ijpharm_2004_11_011 crossref_primary_10_1002_jps_21499 crossref_primary_10_1016_j_foodres_2016_10_049 crossref_primary_10_1016_j_ijpharm_2019_118865 crossref_primary_10_1016_j_ejpb_2010_10_005 crossref_primary_10_1016_j_ijpharm_2013_04_034 crossref_primary_10_1016_j_ijpharm_2013_12_003 crossref_primary_10_1080_10408398_2019_1707770 crossref_primary_10_1016_S0169_409X_01_00184_3 crossref_primary_10_1021_mp100149j crossref_primary_10_1016_j_xphs_2018_10_051 crossref_primary_10_1002_jps_24511 crossref_primary_10_1016_j_ejps_2014_02_010 crossref_primary_10_1016_j_foodres_2013_11_017 crossref_primary_10_1016_j_ijpharm_2013_11_062 crossref_primary_10_1016_j_ejpb_2020_11_023 crossref_primary_10_1073_pnas_1002292107 crossref_primary_10_1016_j_addr_2021_113925 crossref_primary_10_1016_j_biomaterials_2010_01_045 crossref_primary_10_1208_s12249_011_9689_8 crossref_primary_10_1016_S0378_5173_01_00844_4 crossref_primary_10_1016_j_jddst_2024_105563 crossref_primary_10_1080_03639040801926683 crossref_primary_10_1208_s12249_014_0225_5 crossref_primary_10_3109_10837450_2013_823990 crossref_primary_10_3109_03639045_2011_645836 crossref_primary_10_1109_JSEN_2016_2627798 crossref_primary_10_1007_s11095_007_9462_6 crossref_primary_10_1016_j_ijpharm_2008_08_016 crossref_primary_10_1557_adv_2019_370 crossref_primary_10_7243_2050_120X_1_1 crossref_primary_10_1208_s12249_017_0825_y crossref_primary_10_1517_17425247_2011_592828 crossref_primary_10_1016_j_ces_2014_04_006 crossref_primary_10_1557_s43579_021_00024_0 crossref_primary_10_1007_s11095_005_5272_x crossref_primary_10_3109_03639040903311081 crossref_primary_10_1016_j_ejpb_2016_10_027 crossref_primary_10_1080_09205063_2012_703950 crossref_primary_10_1016_j_foodhyd_2020_106166 crossref_primary_10_1021_mp300604u crossref_primary_10_1016_j_addr_2021_113943 crossref_primary_10_1016_j_foodres_2020_109296 crossref_primary_10_1016_j_ijpharm_2011_12_034 crossref_primary_10_1039_C4FO00700J crossref_primary_10_1016_S0939_6411_01_00222_3 crossref_primary_10_1016_j_jddst_2019_101338 crossref_primary_10_1557_s43580_021_00196_w crossref_primary_10_3390_pharmaceutics11060271 crossref_primary_10_1517_17425247_2010_527943 crossref_primary_10_1016_j_ijpharm_2018_04_005 crossref_primary_10_1007_s11094_022_02786_w crossref_primary_10_1016_j_foodres_2020_109782 crossref_primary_10_1016_S0378_5173_02_00535_5 crossref_primary_10_1016_j_jddst_2020_102034 crossref_primary_10_1111_j_2042_7158_2012_01477_x crossref_primary_10_1016_j_device_2023_100055 crossref_primary_10_1248_cpb_56_1234 crossref_primary_10_1016_j_ejps_2016_08_060 crossref_primary_10_1016_j_foodres_2022_111837 crossref_primary_10_1016_S0378_5173_02_00043_1 crossref_primary_10_1039_D0FO01981J crossref_primary_10_1016_j_foodres_2016_02_019 crossref_primary_10_1016_S0168_3659_03_00203_7 crossref_primary_10_1186_1476_511X_10_51 crossref_primary_10_1016_j_ejpb_2004_02_003 crossref_primary_10_6090_jarq_51_17 crossref_primary_10_1080_03639045_2017_1323910 crossref_primary_10_1016_j_ijpharm_2015_02_040 crossref_primary_10_1016_j_jtbi_2023_111418 crossref_primary_10_1208_s12248_021_00590_0 crossref_primary_10_2165_00063030_200822040_00002 crossref_primary_10_1016_j_ijpharm_2005_12_037 crossref_primary_10_1208_s12249_011_9608_z crossref_primary_10_1016_j_ejpb_2014_07_009 crossref_primary_10_1016_j_eurpolymj_2015_12_029 |
Cites_doi | 10.1248/bpb1978.7.656 10.1016/S0016-5085(19)32458-8 10.1023/A:1015855829864 10.1111/j.1365-2125.1986.tb02937.x 10.1016/0378-5173(94)90356-5 10.1023/A:1015987016003 10.1002/jps.2600750313 10.1002/jps.2600550305 10.1023/A:1016231010301 10.1023/A:1015894626403 10.1002/jps.2600630136 10.1111/j.2042-7158.1988.tb05220.x 10.1016/0378-5173(96)04489-4 10.1136/gut.27.8.886 10.1016/S0016-5085(79)80182-1 10.1023/A:1016270701021 10.1136/gut.24.9.790 |
ContentType | Journal Article |
Copyright | 2000 Elsevier Science B.V. 2000 INIST-CNRS |
Copyright_xml | – notice: 2000 Elsevier Science B.V. – notice: 2000 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/S0378-5173(00)00552-4 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-3476 |
EndPage | 70 |
ExternalDocumentID | 11064212 1523101 10_1016_S0378_5173_00_00552_4 S0378517300005524 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29J 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXUO ABFNM ABFRF ABJNI ABMAC ABOCM ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SPCBC SPT SSP SSZ T5K TEORI WUQ ZXP ~02 ~G- AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION SSH EFKBS IQODW CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c390t-90c67786d5fc63f355c9b9c27fd530dc79a1d6e8d2a349c00372bfe409ebb32e3 |
IEDL.DBID | AIKHN |
ISSN | 0378-5173 |
IngestDate | Fri Jul 11 06:16:40 EDT 2025 Wed Feb 19 02:36:11 EST 2025 Mon Jul 21 09:16:12 EDT 2025 Thu Apr 24 23:04:45 EDT 2025 Tue Jul 01 04:15:26 EDT 2025 Fri Feb 23 02:29:29 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Teflon Gastrointestinal transit Riboflavin Stomach Destructive force Structure stability Disintegration Hydrophobicity Powder compact Release Physical structure Human Urine Pharmaceutical technology Healthy subject Digestive system Oral administration Mechanical properties Direct compression Dissolution In vitro Pressure Physical properties In vivo Destructive test Dosage form Pharmacokinetics Physicochemical properties |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c390t-90c67786d5fc63f355c9b9c27fd530dc79a1d6e8d2a349c00372bfe409ebb32e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 11064212 |
PQID | 72390258 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_72390258 pubmed_primary_11064212 pascalfrancis_primary_1523101 crossref_citationtrail_10_1016_S0378_5173_00_00552_4 crossref_primary_10_1016_S0378_5173_00_00552_4 elsevier_sciencedirect_doi_10_1016_S0378_5173_00_00552_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2000-11-04 |
PublicationDateYYYYMMDD | 2000-11-04 |
PublicationDate_xml | – month: 11 year: 2000 text: 2000-11-04 day: 04 |
PublicationDecade | 2000 |
PublicationPlace | Amsterdam |
PublicationPlace_xml | – name: Amsterdam – name: Netherlands |
PublicationTitle | International journal of pharmaceutics |
PublicationTitleAlternate | Int J Pharm |
PublicationYear | 2000 |
Publisher | Elsevier B.V Elsevier |
Publisher_xml | – name: Elsevier B.V – name: Elsevier |
References | Davis, Norring-Christensen, Khosla, Feely (BIB4) 1988; 40 Chan, Mojaverian, Ziehmer, John (BIB1) 1990; 7 Levy, Jusko (BIB8) 1966; 55 Shameem, Katori, Aoyagi, Kojima (BIB13) 1995; 12 Ogata, Aoyagi, Kaniwa, Ejima, Suzuki, Ishioka, Morishita, Ohta, Takagishi, Doi, Ogura (BIB12) 1984; 7 Meyer, Thompson, Cohen (BIB10) 1979; 76 Steffensen, Pedersen (BIB15) 1986; 22 Coupe, Davis, Evans, Wilding (BIB2) 1991; 8 Stemper, Cooke (BIB16) 1975; 69 Ferrari, Bertoni, Bonferoni, Rossi, Caramella, Nyström (BIB5) 1996; 136 Stanghellini, Malagelada (BIB14) 1983; 24 Kenyon, Cole, Wilding (BIB7) 1994; 112 Lui, Amidon, Berardi, Fleischer, Youngberg, Dressman (BIB9) 1986; 75 Katori, Aoyagi, Terao (BIB6) 1995; 12 Mojaverian, Reynolds, Ouyang, Wirth, Kellner, Vlasses (BIB11) 1991; 8 Wan, Lee (BIB17) 1974; 63 Davis, Hardy, Fara (BIB3) 1986; 27 Ogata (10.1016/S0378-5173(00)00552-4_BIB12) 1984; 7 Mojaverian (10.1016/S0378-5173(00)00552-4_BIB11) 1991; 8 Ferrari (10.1016/S0378-5173(00)00552-4_BIB5) 1996; 136 Meyer (10.1016/S0378-5173(00)00552-4_BIB10) 1979; 76 Shameem (10.1016/S0378-5173(00)00552-4_BIB13) 1995; 12 Kenyon (10.1016/S0378-5173(00)00552-4_BIB7) 1994; 112 Stemper (10.1016/S0378-5173(00)00552-4_BIB16) 1975; 69 Levy (10.1016/S0378-5173(00)00552-4_BIB8) 1966; 55 Stanghellini (10.1016/S0378-5173(00)00552-4_BIB14) 1983; 24 Steffensen (10.1016/S0378-5173(00)00552-4_BIB15) 1986; 22 Davis (10.1016/S0378-5173(00)00552-4_BIB4) 1988; 40 Wan (10.1016/S0378-5173(00)00552-4_BIB17) 1974; 63 Coupe (10.1016/S0378-5173(00)00552-4_BIB2) 1991; 8 Chan (10.1016/S0378-5173(00)00552-4_BIB1) 1990; 7 Lui (10.1016/S0378-5173(00)00552-4_BIB9) 1986; 75 Davis (10.1016/S0378-5173(00)00552-4_BIB3) 1986; 27 Katori (10.1016/S0378-5173(00)00552-4_BIB6) 1995; 12 |
References_xml | – volume: 12 start-page: 237 year: 1995 end-page: 243 ident: BIB6 article-title: Estimation of agitation intensity in the GI tract in humans and dogs based on in vitro/in vivo correlation publication-title: Pharm. Res. – volume: 76 start-page: 801 year: 1979 end-page: 813 ident: BIB10 article-title: Sieving of solid food by the canine stomach and sieving after gastric surgery publication-title: Gastroenterology – volume: 112 start-page: 207 year: 1994 end-page: 213 ident: BIB7 article-title: The effect of food on the in vivo behaviour of enteric coated starch capsules publication-title: Int. J. Pharm. – volume: 8 start-page: 1281 year: 1991 end-page: 1285 ident: BIB2 article-title: Correlation of the gastric emptying of non-disintegrating tablets with gastrointestinal motility publication-title: Pharm. Res. – volume: 55 start-page: 285 year: 1966 end-page: 289 ident: BIB8 article-title: Factors affecting the absorption of riboflavin in man publication-title: J. Pharm. Sci. – volume: 12 start-page: 1049 year: 1995 end-page: 1054 ident: BIB13 article-title: Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasting and fed conditions in humans publication-title: Pharm. Res. – volume: 24 start-page: 790 year: 1983 end-page: 797 ident: BIB14 article-title: Gastric manometric abnormalities in patients with dyspeptic symptoms after fundoplication publication-title: Gut – volume: 8 start-page: 97 year: 1991 end-page: 100 ident: BIB11 article-title: Mechanism of gastric emptying of a non-disintegrating radiotelemetry capsule in man publication-title: Pharm. Res. – volume: 69 start-page: 649 year: 1975 end-page: 653 ident: BIB16 article-title: Gastric emptying and its relationship to antral contractile activity publication-title: Gastroenterogy – volume: 27 start-page: 886 year: 1986 end-page: 892 ident: BIB3 article-title: Transit of pharmaceutical dosage forms through the small intestine publication-title: Gut – volume: 40 start-page: 205 year: 1988 end-page: 207 ident: BIB4 article-title: Gastric emptying of large single unit dosage forms publication-title: J. Pharm. Pharmacol. – volume: 22 start-page: 571 year: 1986 end-page: 577 ident: BIB15 article-title: Food induced changes in theophylline absorption from a once a day theophylline project publication-title: Br. J. Clin. Pharmac. – volume: 7 start-page: 656 year: 1984 end-page: 664 ident: BIB12 article-title: Development and evaluation of a new peroral test agent GA-test for assessment of gastric acidity publication-title: J. Pharm. Dyn. – volume: 136 start-page: 71 year: 1996 end-page: 79 ident: BIB5 article-title: Investigation on bonding and disintegration properties of pharmaceutical materials publication-title: Int. J. Pharm. – volume: 75 start-page: 271 year: 1986 end-page: 274 ident: BIB9 article-title: Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans publication-title: J. Pharm. Sci. – volume: 63 start-page: 136 year: 1974 end-page: 137 ident: BIB17 article-title: CMC of polysorbates publication-title: J. Pharm. Sci. – volume: 7 start-page: 1026 year: 1990 end-page: 1032 ident: BIB1 article-title: Application of radio telemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers publication-title: Pharm. Res. – volume: 7 start-page: 656 year: 1984 ident: 10.1016/S0378-5173(00)00552-4_BIB12 article-title: Development and evaluation of a new peroral test agent GA-test for assessment of gastric acidity publication-title: J. Pharm. Dyn. doi: 10.1248/bpb1978.7.656 – volume: 69 start-page: 649 year: 1975 ident: 10.1016/S0378-5173(00)00552-4_BIB16 article-title: Gastric emptying and its relationship to antral contractile activity publication-title: Gastroenterogy doi: 10.1016/S0016-5085(19)32458-8 – volume: 8 start-page: 1281 year: 1991 ident: 10.1016/S0378-5173(00)00552-4_BIB2 article-title: Correlation of the gastric emptying of non-disintegrating tablets with gastrointestinal motility publication-title: Pharm. Res. doi: 10.1023/A:1015855829864 – volume: 22 start-page: 571 year: 1986 ident: 10.1016/S0378-5173(00)00552-4_BIB15 article-title: Food induced changes in theophylline absorption from a once a day theophylline project publication-title: Br. J. Clin. Pharmac. doi: 10.1111/j.1365-2125.1986.tb02937.x – volume: 112 start-page: 207 year: 1994 ident: 10.1016/S0378-5173(00)00552-4_BIB7 article-title: The effect of food on the in vivo behaviour of enteric coated starch capsules publication-title: Int. J. Pharm. doi: 10.1016/0378-5173(94)90356-5 – volume: 7 start-page: 1026 year: 1990 ident: 10.1016/S0378-5173(00)00552-4_BIB1 article-title: Application of radio telemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers publication-title: Pharm. Res. doi: 10.1023/A:1015987016003 – volume: 75 start-page: 271 year: 1986 ident: 10.1016/S0378-5173(00)00552-4_BIB9 article-title: Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600750313 – volume: 55 start-page: 285 year: 1966 ident: 10.1016/S0378-5173(00)00552-4_BIB8 article-title: Factors affecting the absorption of riboflavin in man publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600550305 – volume: 12 start-page: 237 year: 1995 ident: 10.1016/S0378-5173(00)00552-4_BIB6 article-title: Estimation of agitation intensity in the GI tract in humans and dogs based on in vitro/in vivo correlation publication-title: Pharm. Res. doi: 10.1023/A:1016231010301 – volume: 8 start-page: 97 year: 1991 ident: 10.1016/S0378-5173(00)00552-4_BIB11 article-title: Mechanism of gastric emptying of a non-disintegrating radiotelemetry capsule in man publication-title: Pharm. Res. doi: 10.1023/A:1015894626403 – volume: 63 start-page: 136 year: 1974 ident: 10.1016/S0378-5173(00)00552-4_BIB17 article-title: CMC of polysorbates publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600630136 – volume: 40 start-page: 205 year: 1988 ident: 10.1016/S0378-5173(00)00552-4_BIB4 article-title: Gastric emptying of large single unit dosage forms publication-title: J. Pharm. Pharmacol. doi: 10.1111/j.2042-7158.1988.tb05220.x – volume: 136 start-page: 71 year: 1996 ident: 10.1016/S0378-5173(00)00552-4_BIB5 article-title: Investigation on bonding and disintegration properties of pharmaceutical materials publication-title: Int. J. Pharm. doi: 10.1016/0378-5173(96)04489-4 – volume: 27 start-page: 886 year: 1986 ident: 10.1016/S0378-5173(00)00552-4_BIB3 article-title: Transit of pharmaceutical dosage forms through the small intestine publication-title: Gut doi: 10.1136/gut.27.8.886 – volume: 76 start-page: 801 year: 1979 ident: 10.1016/S0378-5173(00)00552-4_BIB10 article-title: Sieving of solid food by the canine stomach and sieving after gastric surgery publication-title: Gastroenterology doi: 10.1016/S0016-5085(79)80182-1 – volume: 12 start-page: 1049 year: 1995 ident: 10.1016/S0378-5173(00)00552-4_BIB13 article-title: Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasting and fed conditions in humans publication-title: Pharm. Res. doi: 10.1023/A:1016270701021 – volume: 24 start-page: 790 year: 1983 ident: 10.1016/S0378-5173(00)00552-4_BIB14 article-title: Gastric manometric abnormalities in patients with dyspeptic symptoms after fundoplication publication-title: Gut doi: 10.1136/gut.24.9.790 |
SSID | ssj0006213 |
Score | 2.0039904 |
Snippet | The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 61 |
SubjectTerms | Adult Biological and medical sciences Biomechanical Phenomena Compressive Strength Destructive force Fasting - urine Gastrointestinal Contents Gastrointestinal Motility - physiology Gastrointestinal transit General pharmacology Humans Male Medical sciences Middle Aged Particle Size Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Photosensitizing Agents - chemistry Photosensitizing Agents - urine Polytetrafluoroethylene - chemistry Polytetrafluoroethylene - pharmacokinetics Powders Riboflavin Riboflavin - chemistry Riboflavin - urine Solubility Stomach Tablets Teflon |
Title | A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract |
URI | https://dx.doi.org/10.1016/S0378-5173(00)00552-4 https://www.ncbi.nlm.nih.gov/pubmed/11064212 https://www.proquest.com/docview/72390258 |
Volume | 208 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZ5XAqhNEmbbpuHDiG0EGdlSbbXxyUkbFsaAk0gN6FnWGjthd0t5NLf3hlZG5NDCORqa2RZM5r5ZGu-IeS4qiDsCxOyKtc2k1b7zBhrMqeFL21tdMgxUfjnVTm5ld_virs1cr7KhcFjlcn3dz49eut0ZZhmczibToe_mIiF5QW63KLgcp1sclGXYNqb428_JlePDrnkqUoybJhQoE_k6TqJF78w9jX2k8nnQtTWTM9h4kJX8eJ5SBpD0-U78jZhSjruhr1N1nyzQ06uO1Lqh1N60-dYzU_pCb3u6aofdoka02VkcaWuxVNmFGEsXbQ0EYF7ChiR_vGYIowapc4n0tm_sa31dNrENvcabrRIQAF-A0e0wBSs9-T28uLmfJKlsguZFTVbZDWzkVXOFcGWIgAgAZ3VllfBFYI5W9U6d6UfOa6FrC0y2HATPGwUvTGCe_GBbDRt4z8S6oXmgelQ5bmTxjkDaDE46EIbZrQYDYhczbSyiZMcS2P8Vv3hM1CQQgUphkSmoCAlB-TsUWzWkXK8JDBaqVE9sS4FgeMl0YMnau8fWCA0zgfkaGUGClYm_m7RjW-Xc1WBNQKihJfc66yjF81jfjH_9PphfSZvIikAfuCW-2QD9O4PAB4tzCFZP_uXH6ZF8B86QAtf |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dSxwxEA9WH1ooRft59SsPRVpwvWyS3b19FFFOqyL0BN9CPstBu3twZ8GX_u3OZHMuPojgazaTzWY-MtnM_IaQb1UF274wIatybTNptc-MsSZzWvjS1kaHHBOFLy7L8bU8uyluVsjRMhcGwyqT7e9serTWqWWYVnM4m06Hv5iIheUFmtyi4PIVWZOgvqidB__7OI-SpxrJcFzC7n0aTzdEbPzO2I84Siaf2qDezvQcli109S6edkjjxnSyTt4lj5IedpPeICu-eU_2rjpI6rt9OukzrOb7dI9e9WDVdx-IOqS3EcOVuhZjzCg6sXTR0gQD7il4iPSvxwRh5Cd1PkHO_ot9rafTJvb5reFBi_ATYDVwRgtMwPpIrk-OJ0fjLBVdyKyo2SKrmY2Ycq4IthQB3BHgWG15FVwhmLNVrXNX-pHjWsjaIn4NN8HDMdEbI7gXn8hq0zb-C6FeaB6YDlWeO2mcM-ArBgdDaMOMFqMBkcuVVjYhkmNhjD-qDz0DBilkkGIIYwoMUnJADh7IZh0kx3MEoyUb1SPZUrBtPEe6_Yjt_QsLdIzzAdldioECvcTLFt349nauKi7wBhc-8nMnHT1pHrOL-deXT2uXvB5PLs7V-enlz03yJsID4K9uuUVWQQb8NjhKC7MTFeEeYlcMIw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+unique+dosage+form+to+evaluate+the+mechanical+destructive+force+in+the+gastrointestinal+tract&rft.jtitle=International+journal+of+pharmaceutics&rft.au=Kamba%2C+Masaharu&rft.au=Seta%2C+Yasuo&rft.au=Kusai%2C+Akira&rft.au=Ikeda%2C+Masaru&rft.date=2000-11-04&rft.pub=Elsevier+B.V&rft.issn=0378-5173&rft.eissn=1873-3476&rft.volume=208&rft.issue=1&rft.spage=61&rft.epage=70&rft_id=info:doi/10.1016%2FS0378-5173%2800%2900552-4&rft.externalDocID=S0378517300005524 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-5173&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-5173&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-5173&client=summon |